BR112018013928A2 - therapeutic compositions and methods for treating hepatitis b - Google Patents

therapeutic compositions and methods for treating hepatitis b

Info

Publication number
BR112018013928A2
BR112018013928A2 BR112018013928-9A BR112018013928A BR112018013928A2 BR 112018013928 A2 BR112018013928 A2 BR 112018013928A2 BR 112018013928 A BR112018013928 A BR 112018013928A BR 112018013928 A2 BR112018013928 A2 BR 112018013928A2
Authority
BR
Brazil
Prior art keywords
inhibitor
reverse transcriptase
capsid
sag secretion
hepatitis
Prior art date
Application number
BR112018013928-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Cuconati Andrea
C. H. Lee Amy
A. Rijnbrand Cornelis
J. Sofia Michael
Original Assignee
Arbutus Biopharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59274445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018013928(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arbutus Biopharma Corporation filed Critical Arbutus Biopharma Corporation
Publication of BR112018013928A2 publication Critical patent/BR112018013928A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
BR112018013928-9A 2016-01-08 2017-01-06 therapeutic compositions and methods for treating hepatitis b BR112018013928A2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662276722P 2016-01-08 2016-01-08
US62/276,722 2016-01-08
US201662343514P 2016-05-31 2016-05-31
US62/343,514 2016-05-31
US201662345476P 2016-06-03 2016-06-03
US62/345,476 2016-06-03
US201662409180P 2016-10-17 2016-10-17
US62/409,180 2016-10-17
US201662420969P 2016-11-11 2016-11-11
US62/420,969 2016-11-11
PCT/US2017/012614 WO2017120527A2 (en) 2016-01-08 2017-01-06 Therapeutic compositions and methods for treating hepatitis b

Publications (1)

Publication Number Publication Date
BR112018013928A2 true BR112018013928A2 (en) 2018-12-11

Family

ID=59274445

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013928-9A BR112018013928A2 (en) 2016-01-08 2017-01-06 therapeutic compositions and methods for treating hepatitis b

Country Status (16)

Country Link
US (2) US20190282604A1 (https=)
EP (1) EP3400008A4 (https=)
JP (3) JP2019501202A (https=)
KR (2) KR20180120675A (https=)
CN (1) CN110022895A (https=)
AU (3) AU2017205650A1 (https=)
BR (1) BR112018013928A2 (https=)
CA (1) CA3009996A1 (https=)
CL (2) CL2018001858A1 (https=)
CO (1) CO2018008249A2 (https=)
HK (1) HK1255835A1 (https=)
IL (2) IL295692A (https=)
PH (1) PH12018501455A1 (https=)
SG (2) SG10201912314QA (https=)
TW (4) TW201735950A (https=)
WO (1) WO2017120527A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4512407A3 (en) 2018-07-13 2025-09-24 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
US20200332297A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
MA55720A (fr) * 2019-04-18 2022-02-23 Janssen Pharmaceuticals Inc Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
CN114828852A (zh) * 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
US12569500B2 (en) 2020-05-15 2026-03-10 Fujian Akeylink Biotechnology Co., Ltd. Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV
JP2024537830A (ja) * 2021-10-08 2024-10-16 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド カプシドタンパク質阻害剤と逆転写酵素阻害剤とを含む医薬組合せ
CN117771361B (zh) * 2024-02-27 2024-06-07 天津中逸安健生物科技有限公司 一种聚肌苷酸-聚胞苷酸复合物的脂质纳米佐剂及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809083B1 (en) * 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
WO2004050613A2 (en) * 2002-12-02 2004-06-17 Gilead Sciences, Inc. 2-substituted-3-propenamide derivatives and methods of using the same
US20110218512A1 (en) * 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
SG181633A1 (en) * 2009-12-31 2012-07-30 xiao-jian Zhou Compositions and methods for treating hepatitis b virus infection
WO2012024170A2 (en) * 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2013308045B2 (en) * 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
US8993771B2 (en) * 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
CA2948580A1 (en) * 2014-05-09 2015-11-12 Adam Zlotnick Methods and compositions for treating hepatitis b virus infections
US10550084B2 (en) * 2017-12-04 2020-02-04 Arbutus Biopharma Corporation Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same
US10358447B2 (en) * 2017-12-04 2019-07-23 Arbutus Biopharma Corporation Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same

Also Published As

Publication number Publication date
TW202211912A (zh) 2022-04-01
TW202322791A (zh) 2023-06-16
TW202435851A (zh) 2024-09-16
JP2024105468A (ja) 2024-08-06
AU2017205650A1 (en) 2018-07-19
US20240050463A1 (en) 2024-02-15
KR20180120675A (ko) 2018-11-06
SG10201912314QA (en) 2020-02-27
CN110022895A (zh) 2019-07-16
TW201735950A (zh) 2017-10-16
CL2018001858A1 (es) 2018-11-23
PH12018501455A1 (en) 2019-03-18
WO2017120527A2 (en) 2017-07-13
EP3400008A4 (en) 2019-10-09
CA3009996A1 (en) 2017-07-13
HK1255835A1 (zh) 2019-08-30
EP3400008A2 (en) 2018-11-14
IL303754A (en) 2023-08-01
CL2023000892A1 (es) 2023-09-29
IL295692A (en) 2022-10-01
US20190282604A1 (en) 2019-09-19
WO2017120527A3 (en) 2017-08-31
AU2025217340A1 (en) 2025-11-06
JP2019501202A (ja) 2019-01-17
SG11201805729SA (en) 2018-08-30
AU2022203814A1 (en) 2022-06-23
KR20250089561A (ko) 2025-06-18
CO2018008249A2 (es) 2018-08-21
JP2022087209A (ja) 2022-06-09

Similar Documents

Publication Publication Date Title
US20250000797A1 (en) Nanomaterials
EP3400008A2 (en) Therapeutic compositions and methods for treating hepatitis b
ES2613498T3 (es) Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US10081598B2 (en) Cationic lipid
US11904052B2 (en) Methods for ameliorating infusion reactions
EP3634431A1 (en) Therapeutic compositions and methods for treating hepatitis b
WO2019051257A2 (en) METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
WO2016071857A1 (en) Compositions and methods for silencing ebola virus expression
WO2018232330A1 (en) Therapeutic compositions and methods for treating hepatitis b
EP4653462A2 (en) Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
HK40127056A (en) Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]